These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

36 related articles for article (PubMed ID: 1669174)

  • 21. [The effect of one-month antithyroid therapy on peripheral metabolism of reactive oxygen species in Graves' disease with infiltrative ophthalmopathy].
    Bednarek J; Wysocki H; Sowiński J
    Przegl Lek; 2004; 61(8):841-4. PubMed ID: 15789912
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Taste disorders and liver parenchymal damage after administration of thiamazole (author's transl)].
    Kolenda KD
    Dtsch Med Wochenschr; 1976 Jan; 101(3):84-6. PubMed ID: 1245162
    [TBL] [Abstract][Full Text] [Related]  

  • 23. 2-Mercapto-1-methyl-5-methylmercapto-imidazole: a new metabolite of thiamazole.
    Twele R; Kern W; Spiteller G
    Xenobiotica; 1983 Nov; 13(11):661-8. PubMed ID: 6673377
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pharmacokinetic parameters of thiamazole in hyperthyroid patients responding rapidly and slowly to the treatment.
    Syrenicz A; Gawrońska-Szklarz B; Wójcicki J; Czekalski S
    Pol J Pharmacol Pharm; 1991; 43(3):207-12. PubMed ID: 1961693
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Serum thyroxine and triiodothyronine levels after a single dose and after 2-month-long thiamazole treatment of Graves' disease with reference to drug's pharmacokinetics].
    Syrenicz A
    Ann Acad Med Stetin; 1990; 36():133-52. PubMed ID: 2099104
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Acetylation phenotype in Graves' disease].
    Górnik W; Syrenicz A; Gawrońska-Szklarz B; Wójcicki J
    Pol Tyg Lek; 1989 Aug 7-14; 44(32-33):743-5. PubMed ID: 2641798
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Activity of antioxidative enzymes and concentration of malondialdehyde as oxidative status markers in women with newly diagnosed Graves-Basedow disease and after thiamazole therapy leading to euthyroidism.
    Rybus-Kalinowska B; Zwirska-Korczala K; Kalinowski M; Kukla M; Birkner E; Jochem J
    Pol Arch Med Wewn; 2008; 118(7-8):420-5. PubMed ID: 18714737
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Pharmacokinetics of phenazone in patients with fast and slow euthyroidism after methimazole treatment].
    Wójcicki J; Górnik W; Syrenicz A; Gawrońska-Szklarz B; Czekalski S
    Pol Tyg Lek; 1990 Feb 5-12; 45(6-7):131-3. PubMed ID: 2216952
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Comparison of thiamazole pharmacokinetics in healthy individuals and patients with hyperthyroidism].
    Syrenicz A; Gawrońska-Szklarz B; Wójcicki J; Czekalski S
    Pol Tyg Lek; 1991 Oct 28-Nov 4; 46(43-44):838-40. PubMed ID: 1669174
    [TBL] [Abstract][Full Text] [Related]  

  • 30.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 31.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 32.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 33.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 34.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 35.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 36.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]     [New Search]
    of 2.